GlassScriptPhysician profile
James L Rycyna
NPI 1770556631
$623.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $162 · 2021: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.77 | 2019-2020 | |
| Amgen INC. | $213.88 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $27.65 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.62 | 2019-2020 | |
| Pfizer INC. | $24.94 | 2019-2021 | |
| Abbott Laboratories | $20.94 | 2019 | |
| Lemaitre Vascular, INC. | $18.18 | 2020 | |
| Edwards Lifesciences Corporation | $16.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.10 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$49,999.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rycyna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.